tiprankstipranks

Alkermes price target raised to $38 from $35 at TD Cowen

TD Cowen analyst Joseph Thome raised the firm’s price target on Alkermes (ALKS) to $38 from $35. The firm said total Q4 revenue came in above expectations supported by beats from Vivitrol and Aristada as well as solid performance from Lybalvi.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue